EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Neuroprotective Activity of Rasayana Formulation and Effect of Shigru Pallava Eye Drops on Intraocular Pressure as an Add-on Therapy Compared to the Standard of Care in Primary Open-Angle Glaucoma: Protocol for an Exploratory, Open-label, Two-arm Randomized Controlled Trial

Deenadayal Devarajan iD, Manjusha Rajagopala iD

F1000Research · 2025

DOI: 10.12688/f1000research.163722.1 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift F1000Research, 2025. Verfasst von Deenadayal Devarajan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Shalakya Tantra, All India Institute of Ayurveda, New Delhi, 110076, India. Hauptthemen laut MEDLINE: Glaucoma, Open-Angle, Intraocular Pressure, Neuroprotective Agents, Ophthalmic Solutions. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: All India Institute of Ayurveda, New Delhi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary open-angle glaucoma (POAG) is a major cause of irreversible blindness worldwide, characterized by progressive optic neuropathy and loss of retinal ganglion cells (RGCs). Although lowering intraocular pressure (IOP) remains the mainstay of glaucoma management, many patients continue to experience vision loss, underscoring the need for adjunctive neuroprotective approaches. In Ayurveda, Rasayana therapies are believed to slow degenerative processes. One such intervention is a Rasayana Formulation (RF) comprising three oral preparations; Rasayana Churna (RC), Saptamrita Lauha (SL), and Yashada Bhasma (YB). Additionally, topical Arka (distilled extract) of Shigru Pallava (SP) has been used traditionally for glaucoma and may have an IOP-lowering effect.

Methods

This is an open-label, two-arm, parallel-group randomized controlled trial with a 2:3 (control: intervention) allocation ratio. A total of 50 previously or newly diagnosed POAG patients (IOP < 30 mmHg) are planned for enrollment. The control group receives the conventional standard of care alone, whereas the intervention group receives standard care plus RF (2.5 g, taken orally twice daily) and SP eye drops (1 drop, four times daily), administered for 90 days with a further 90-day follow-up. Primary outcomes include changes in optic nerve function measured by visual field indices (mean deviation (MD), pattern standard deviation (PSD), visual field index (VFI)) and retinal nerve fiber layer (RNFL) thickness, while secondary outcomes include IOP changes.

Results

Participant recruitment and data collection are ongoing. Final outcomes will be disseminated in peer-reviewed journals.

Conclusions

If shown to be effective, the combined RF and SP eye drops could enhance neuroprotection and further control IOP in POAG, thereby addressing a significant need in current glaucoma therapy. This trial may provide a foundation for larger-scale investigations into integrative treatments for glaucoma management. Trial Registration Clinical Trial Registry of India (CTRI) no. CTRI/2023/06/053681, dated 08.06.2023. Available from: https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2023/06/053681 Protocol Version: 3.0, dated 05.01.2023

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glaucoma, Open-AngleIntraocular PressureNeuroprotective AgentsOphthalmic SolutionsPlant ExtractsAdultFemaleHumansMaleMiddle AgedRandomized Controlled Trials as TopicStandard of Care

Stichwörter der Autor:innen

AyurvedaGlaucomaIntraocular PressureNeuroprotectionProtocolRasayanaShigru PallavaTimira

Substanzen

Neuroprotective AgentsOphthalmic SolutionsPlant Extracts

Autor:innen und Institutionen

  • Shalakya Tantra, All India Institute of Ayurveda, New Delhi, 110076, India.

ORCID-Profile: Deenadayal Devarajan, Manjusha Rajagopala

Förderung

  • All India Institute of Ayurveda, New Delhi

Zitieren

APA

Devarajan, D., & Rajagopala, M. (2025). Neuroprotective Activity of Rasayana Formulation and Effect of Shigru Pallava Eye Drops on Intraocular Pressure as an Add-on Therapy Compared to the Standard of Care in Primary Open-Angle Glaucoma: Protocol for an Exploratory, Open-label, Two-arm Randomized Controlled Trial. F1000Research. https://doi.org/10.12688/f1000research.163722.1

Vancouver

Devarajan D, Rajagopala M. Neuroprotective Activity of Rasayana Formulation and Effect of Shigru Pallava Eye Drops on Intraocular Pressure as an Add-on Therapy Compared to the Standard of Care in Primary Open-Angle Glaucoma: Protocol for an Exploratory, Open-label, Two-arm Randomized Controlled Trial. F1000Research. 2025. doi:10.12688/f1000research.163722.1

BibTeX
@article{Devarajan2025,
  author = {Devarajan, Deenadayal and Rajagopala, Manjusha},
  title = {Neuroprotective Activity of Rasayana Formulation and Effect of Shigru Pallava Eye Drops on Intraocular Pressure as an Add-on Therapy Compared to the Standard of Care in Primary Open-Angle Glaucoma: Protocol for an Exploratory, Open-label, Two-arm Randomized Controlled Trial},
  journal = {F1000Research},
  year = {2025},
  doi = {10.12688/f1000research.163722.1}
}
Kostenlos starten →